VTRS DEADLINE REMINDER: Viatris Inc. Investors are Reminded to Contact BFA Law by the June 3 Class Action Deadline (NASDAQ:VTRS)

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, captioned Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company supplying medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented its facilities as being in "good operating condition" and committed to high-quality manufacturing standards, despite a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection significantly impacted Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results, Viatris disclosed that the negative impact from the Indore facility's inspection would lower 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price dropped roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].